StoxSai Life Sciences vs Syngene International: share price & financials comparison
NSE: SAILIFE vs SYNGENE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Syngene International at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹40,972 Cr, against ₹17,936 Cr for Syngene International (SYNGENE). Over the past year Sai Life Sciences has returned +108.9%, compared with -31.3% for Syngene International. On valuation, Sai Life Sciences trades at a lower P/E of 202.3 versus 469.5. Sai Life Sciences earns a higher return on equity (7.5% vs 0.8%). Sai Life Sciences comes out ahead on size, profitability, growth, momentum and technicals. Syngene International comes out ahead on financial health. Across the scored metrics below, Sai Life Sciences leads on 10 and Syngene International on 2. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Syngene International scores 3/10.
| Metric | Sai Life Sciences | Syngene International |
|---|---|---|
| Size | ||
| Market cap | ₹40,972 Cr | ₹17,936 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹3,739 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹0 Cr |
| Valuation | ||
| P/E | 202.3 | 469.5 |
| P/B | 15.24 | 3.69 |
| Dividend yield | — | 0.28% |
| Profitability | ||
| Return on equity | 7.5% | 0.8% |
| Net profit margin | 8.5% | 1.1% |
| Operating margin | 29.5% | 21.3% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | -8.6% |
| Revenue CAGR (multi-year) | — | +11.3% |
| Financial health | ||
| Debt to equity | 0.17 | 0.01 |
| Momentum | ||
| 1-month return | +31.9% | +17.1% |
| 1-year return | +108.9% | -31.3% |
| 3-year CAGR | — | -14.4% |
| 5-year CAGR | — | -5.6% |
| 10-year CAGR | — | +5.1% |
| Distance from 52W high | +0.0% | -33.1% |
| Technicals | ||
| RSI (14) | 93 | 77 |
| Price vs 200-day avg | +56.3% | +5.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Syngene International |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Syngene International?
Sai Life Sciences has a market cap of ₹40,972 Cr and Syngene International has a market cap of ₹17,936 Cr as of 13 Nov 2026.
Which has a lower P/E, Sai Life Sciences or Syngene International?
Sai Life Sciences has the lower P/E: Sai Life Sciences trades at 202.3 and Syngene International at 469.5.
Which gave better returns in the last year, Sai Life Sciences or Syngene International?
Sai Life Sciences did better: Sai Life Sciences returned +108.9% and Syngene International returned -31.3% over one year.
What is the difference between Sai Life Sciences and Syngene International?
Both are NSE-listed companies in Healthcare. Sai Life Sciences is about 2.3 times the size of Syngene International by market cap. In the latest financial year Sai Life Sciences reported revenue of ₹2,192 Cr and Syngene International ₹3,739 Cr. Operating margin is 29.5% for Sai Life Sciences and 21.3% for Syngene International. Debt to equity is 0.17 for Sai Life Sciences and 0.01 for Syngene International.
Which is better, Sai Life Sciences or Syngene International?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sai Life Sciences leads on 10 and Syngene International on 2. Sai Life Sciences is ahead on size, profitability, growth, momentum and technicals. Syngene International is ahead on financial health. On StoxGud's rules-based checklist Sai Life Sciences scores 6/10 and Syngene International scores 3/10. This is information, not advice: consult a SEBI-registered adviser before investing.